CYTK - Cytokinetics, Incorporated News

RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and ra

defenseworld.net

Analyzing Zai Lab (NASDAQ:ZLAB) and Cytokinetics (NASDAQ:CYTK)

Cytokinetics (NASDAQ: CYTK - Get Free Report) and Zai Lab (NASDAQ: ZLAB - Get Free Report) are both

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: C

Cytokinetics Begins ASPEN-HCM Study Evaluating MYQORZO In Adult Patients With Symptomatic Obstructiv

MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity.

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic O

Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Re

Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach

B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for th

marketbeat.com

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference

Cytokinetics NASDAQ: CYTK executives outlined the company's commercial expansion plans, cardiovascul

fool.com

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next

defenseworld.net

Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 3,500 Shares of Stock

Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) EVP Fady Malik sold 3,500 shares of the

Here’s How Much You Would Have Made Owning Cytokinetics Stock In The Last 15 Years

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 15 years by 2.64% on an annuali

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:

defenseworld.net

Robert Blum Sells 97,926 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) CEO Robert Blum sold 97,926 shares of Cy

Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conferenc

Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet

Cytokinetics, Incorporated's stock remains under pressure. At the same time, Myqorzo sales rose 427.

Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program

Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on C

If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 10.3% on an annuali

Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Trans

Cytokinetics to Participate in September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:

zacks.com

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obst

Cytokinetics Investors Weigh Safety Data From Pivotal Trial

Cytokinetics Incorporated (NASDAQ:CYTK) on Friday shared primary results from the ACACIA-HCM Phase 3

Cytokinetics Investors Weigh Safety Data From Pivotal Trial

Cytokinetics reports Phase 3 results for aficamten in treating hypertrophic cardiomyopathy, targetin

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy

Reported Earlier, Cytokinetics Says New Trial Data Strengthens Case For Aficamten Across Heart Condi

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from ACACIA-HCM (As

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking C

Additional Results from ACACIA-HCM Demonstrate Improvements in Cardiac Structure and Diastolic Func

Cytokinetics, Incorporated (CYTK) Discusses Positive Phase III Results From ACACIA-HCM Trial of Afic

If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.78% on an annuali

marketbeat.com

Cytokinetics' Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM

Cytokinetics NASDAQ: CYTK presented primary results from its Phase III ACACIA-HCM trial evaluating a

reuters.com

Cytokinetics eyes expanded use of heart drug after promising late-stage data

Cytokinetics said on Friday detailed late-stage data showed its drug, aficamten, significantly impro

Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the Europea

ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant

Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110

Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises th

JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises

Cytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia See

In the complaint, the Company requests, among other things: a judgment declaring that the Company do

Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112

Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy an

RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lo

Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $110

Citizens analyst Jason N. Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform an

Needham Maintains Buy on Cytokinetics, Raises Price Target to $112

Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the pri

Cytokinetics Q2 EPS $(1.50) Beats $(1.63) Estimate, Sales $28.624M Beat $17.382M Estimate

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which beat the analyst con

Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.02% on an annuali

Cytokinetics Receives UK Marketing Authorization For MYQORZO For Treatment Of Symptomatic Obstructiv

At the same time the National Institute for Health and Care Excellence (NICE) has issued guidance re

New AI ETF Bets on Healthcare's $9 Trillion Opportunity

Tema's new Healthcare AI ETF (HLTH), targets AI-powered drug discovery, diagnostics, robotics an

RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $117

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lo

Cytokinetics To Present Late Breaking Science At ESC Congress, Including Phase 3 ACACIA‑HCM Results

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in

8 Health Care Stocks With Whale Alerts In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

UBS Upgrades Cytokinetics to Buy, Raises Price Target to $115

UBS analyst Ashwani Verma upgrades Cytokinetics (NASDAQ:CYTK) from Neutral to Buy and raises the

Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $118

Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the p

Cytokinetics Opens Applications for Corporate Giving Program, to Fund Health, Science Education and

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced a call for proposals for its annual Cytokin

Cytokinetics Announces First Commercial European Launch Of MYQORZO In Germany For Treatment Of Sympt

European Launch Follows Strong U.S. StartSOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01,

Citigroup Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $99

Citigroup analyst Eric Joseph initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating

JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $97

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises